$BIOLQ
BIOLASE, INC

2021 Q2 Form 10-Q Financial Statement

#000095017021001452 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $9.134M $2.938M $4.783M
YoY Change 210.89% -66.02% -53.68%
Cost Of Revenue $5.093M $1.997M $3.430M
YoY Change 155.03% -62.07% -49.56%
Gross Profit $4.041M $941.0K $1.353M
YoY Change 329.44% -72.16% -61.56%
Gross Profit Margin 44.24% 32.03% 28.29%
Selling, General & Admin $6.090M $4.230M $5.714M
YoY Change 43.97% -26.85% -8.87%
% of Gross Profit 150.71% 449.52% 422.32%
Research & Development $1.162M $690.0K $991.0K
YoY Change 68.41% -38.61% -30.21%
% of Gross Profit 28.76% 73.33% 73.24%
Depreciation & Amortization $86.00K $310.0K $177.0K
YoY Change -72.26% 14.81% -31.4%
% of Gross Profit 2.13% 32.94% 13.08%
Operating Expenses $7.324M $4.920M $6.705M
YoY Change 48.86% -26.75% -12.92%
Operating Profit -$3.283M -$3.979M -$5.352M
YoY Change -17.49% 19.24% 28.04%
Interest Expense -$582.0K -$625.0K $589.0K
YoY Change -6.88% 18.15% -223.22%
% of Operating Profit
Other Income/Expense, Net $2.501M $665.0K $673.0K
YoY Change 276.09% -224.53% -229.17%
Pretax Income -$782.0K -$4.644M -$6.025M
YoY Change -83.16% 19.97% 23.34%
Income Tax -$80.00K $53.00K -$19.00K
% Of Pretax Income
Net Earnings -$702.0K -$4.697M -$6.006M
YoY Change -85.05% 20.47% 22.57%
Net Earnings / Revenue -7.69% -159.87% -125.57%
Basic Earnings Per Share -$0.12 -$0.12 -$0.19
Diluted Earnings Per Share -$0.12 -$0.12 -$0.19
COMMON SHARES
Basic Shares Outstanding 6.027M 37.99M 31.51M
Diluted Shares Outstanding 6.027M 37.99M 31.51M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.08M $5.440M $1.510M
YoY Change 581.64% 46.24% -48.99%
Cash & Equivalents $37.08M $5.749M $1.823M
Short-Term Investments
Other Short-Term Assets $1.725M $1.400M $1.520M
YoY Change 23.21% 11.11% -28.64%
Inventory $12.72M $11.93M $12.19M
Prepaid Expenses
Receivables $3.800M $4.120M $4.750M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $55.34M $22.89M $19.97M
YoY Change 141.76% -15.4% -30.78%
LONG-TERM ASSETS
Property, Plant & Equipment $916.0K $1.430M $1.150M
YoY Change -35.94% -9.78% -52.67%
Goodwill $2.900M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $225.0K $510.0K $484.0K
YoY Change -55.88% -35.69% -221.0%
Total Long-Term Assets $5.909M $4.870M $4.561M
YoY Change 21.33% -8.18% -8.04%
TOTAL ASSETS
Total Short-Term Assets $55.34M $22.89M $19.97M
Total Long-Term Assets $5.909M $4.870M $4.561M
Total Assets $61.25M $27.76M $24.53M
YoY Change 120.64% -14.22% -27.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.502M $2.510M $4.056M
YoY Change 39.52% -57.3% -31.14%
Accrued Expenses $6.461M $2.950M $4.079M
YoY Change 119.02% -39.78% -29.91%
Deferred Revenue $2.056M $1.486M $1.982M
YoY Change 38.36% -40.87% -21.13%
Short-Term Debt $700.0K $13.54M $13.56M
YoY Change -94.83%
Long-Term Debt Due $700.0K $13.56M
YoY Change
Total Short-Term Liabilities $12.72M $21.09M $23.68M
YoY Change -39.69% 58.69% 56.61%
LONG-TERM LIABILITIES
Long-Term Debt $12.70M $3.140M $0.00
YoY Change 304.55% -76.44% -100.0%
Other Long-Term Liabilities $129.0K $2.220M $1.107M
YoY Change -94.19% 18.09% 583.33%
Total Long-Term Liabilities $12.83M $3.140M $1.107M
YoY Change 308.66% -76.44% -90.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.72M $21.09M $23.68M
Total Long-Term Liabilities $12.83M $3.140M $1.107M
Total Liabilities $27.99M $26.45M $25.42M
YoY Change 5.85% -7.43% -5.28%
SHAREHOLDERS EQUITY
Retained Earnings -$259.0M -$240.6M
YoY Change
Common Stock $292.7M $236.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.26M $1.308M -$4.856M
YoY Change
Total Liabilities & Shareholders Equity $61.25M $27.76M $24.53M
YoY Change 120.64% -14.22% -27.44%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$702.0K -$4.697M -$6.006M
YoY Change -85.05% 20.47% 22.57%
Depreciation, Depletion And Amortization $86.00K $310.0K $177.0K
YoY Change -72.26% 14.81% -31.4%
Cash From Operating Activities -$3.508M -$5.210M -$4.134M
YoY Change -32.67% 225.63% -17.88%
INVESTING ACTIVITIES
Capital Expenditures -$301.0K -$70.00K $9.000K
YoY Change 330.0% -41.67% 12.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$301.0K -$70.00K -$9.000K
YoY Change 330.0% -41.67% 12.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.00K 9.130M -117.0K
YoY Change -100.21% 269.64% -4000.0%
NET CHANGE
Cash From Operating Activities -3.508M -5.210M -4.134M
Cash From Investing Activities -301.0K -70.00K -9.000K
Cash From Financing Activities -19.00K 9.130M -117.0K
Net Change In Cash -3.828M 3.850M -4.278M
YoY Change -199.43% 413.33% -15.92%
FREE CASH FLOW
Cash From Operating Activities -$3.508M -$5.210M -$4.134M
Capital Expenditures -$301.0K -$70.00K $9.000K
Free Cash Flow -$3.207M -$5.140M -$4.143M
YoY Change -37.61% 247.3% -17.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
CY2020Q2 biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
dei Entity Central Index Key
EntityCentralIndexKey
0000811240
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
361-1200
dei Security12b Title
Security12bTitle
Common stock at par value $0.001 per share
dei Trading Symbol
TradingSymbol
BIOL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
151193587
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37081000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17564000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
204000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3928000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4017000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3819000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3059000
CY2021Q2 us-gaap Inventory Net
InventoryNet
12715000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11157000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1521000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
225000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2021Q2 us-gaap Assets
Assets
61249000
CY2020Q4 us-gaap Assets
Assets
41025000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3502000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2651000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6461000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6667000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2056000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1905000
CY2021Q2 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
700000
CY2020Q4 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
0
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12719000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3018000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
55340000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35110000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
916000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2021Q2 us-gaap Goodwill
Goodwill
2926000
CY2020Q4 us-gaap Goodwill
Goodwill
2926000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1842000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1976000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11223000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
333000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
374000
CY2021Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
507000
CY2020Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
384000
CY2021Q2 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
12703000
CY2020Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
16186000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1602000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1774000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
129000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1056000
CY2021Q2 us-gaap Liabilities
Liabilities
27993000
CY2020Q4 us-gaap Liabilities
Liabilities
30997000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
35000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
118000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151236000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97709000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151191000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97663000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
151000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
98000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
292517000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
261573000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-468000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258979000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251376000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33256000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10028000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61249000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41025000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9134000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2938000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7721000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
5093000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
1997000
us-gaap Cost Of Revenue
CostOfRevenue
10469000
us-gaap Cost Of Revenue
CostOfRevenue
5427000
CY2021Q2 us-gaap Gross Profit
GrossProfit
4041000
CY2020Q2 us-gaap Gross Profit
GrossProfit
941000
us-gaap Gross Profit
GrossProfit
6781000
us-gaap Gross Profit
GrossProfit
2294000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3311000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2093000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6864000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4797000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2779000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2137000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6134000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5147000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1162000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
690000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2966000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1680000
CY2021Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-72000
CY2020Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-161000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
7324000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
4920000
us-gaap Operating Expenses
OperatingExpenses
16125000
us-gaap Operating Expenses
OperatingExpenses
11624000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3283000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3979000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9344000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9330000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
69000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-136000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-126000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-582000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-625000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1157000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1214000
CY2021Q2 biol Loss Gain On Debt Forgiveness
LossGainOnDebtForgiveness
3014000
CY2020Q2 biol Loss Gain On Debt Forgiveness
LossGainOnDebtForgiveness
0
biol Loss Gain On Debt Forgiveness
LossGainOnDebtForgiveness
3014000
biol Loss Gain On Debt Forgiveness
LossGainOnDebtForgiveness
0
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2501000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
665000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1721000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1340000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-782000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4644000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7623000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10670000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-80000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-702000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4697000
us-gaap Net Income Loss
NetIncomeLoss
-7603000
us-gaap Net Income Loss
NetIncomeLoss
-10704000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
65000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
74000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-83000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
56000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-637000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4623000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7686000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10648000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-702000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4697000
us-gaap Net Income Loss
NetIncomeLoss
-7603000
us-gaap Net Income Loss
NetIncomeLoss
-10704000
CY2021Q2 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
-6000
CY2020Q2 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
-538000
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-708000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4697000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8141000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10704000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150665000
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37990000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142693000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34709000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150665000
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37990000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142693000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34709000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33516000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
366000
CY2021Q2 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
12000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-702000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
65000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33256000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10028000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13291000
biol Issuance Of Common Stock For Settlement Of Liability
IssuanceOfCommonStockForSettlementOfLiability
510000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2062000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
15051000
us-gaap Net Income Loss
NetIncomeLoss
-7603000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-83000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33256000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4856000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3861000
CY2020Q2 biol Sale Of Common Stock Warrants
SaleOfCommonStockWarrants
3031000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3965000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
863000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
708000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
67000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
19000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4697000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
74000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1309000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
378000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3861000
biol Sale Of Common Stock Warrants
SaleOfCommonStockWarrants
3031000
us-gaap Profit Loss
ProfitLoss
-7603000
us-gaap Profit Loss
ProfitLoss
-10704000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
488000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-79000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1008000
us-gaap Inventory Write Down
InventoryWriteDown
-103000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
193000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3965000
biol Adjustments To Additional Paid In Capital Settlement Of Liability Awards
AdjustmentsToAdditionalPaidInCapitalSettlementOfLiabilityAwards
151000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
863000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1348000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
67000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
19000
us-gaap Net Income Loss
NetIncomeLoss
-10704000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
56000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1309000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
84000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
74000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
121000
biol Patent Litigation Mark To Market
PatentLitigationMarkToMarket
161000
biol Patent Litigation Mark To Market
PatentLitigationMarkToMarket
0
us-gaap Share Based Compensation
ShareBasedCompensation
1297000
us-gaap Share Based Compensation
ShareBasedCompensation
1519000
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
3014000
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
682000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3633000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1455000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
937000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-438000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
471000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3835000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
108000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-692000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10008000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9339000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
311000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-311000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
13291000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
3881000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
0
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
3031000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
991000
us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
0
us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
3140000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Repayments Of Debt
RepaymentsOfDebt
3000000
biol Fees Paid For Debt Instruments
FeesPaidForDebtInstruments
0
biol Fees Paid For Debt Instruments
FeesPaidForDebtInstruments
-50000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16550000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
24000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29811000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9011000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-83000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
57000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19409000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-352000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17876000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6101000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37285000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5749000
us-gaap Interest Paid Net
InterestPaidNet
886000
us-gaap Interest Paid Net
InterestPaidNet
466000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
29000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
130000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
26000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
263000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
188000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
35000
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
510000
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
0
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
48000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
570000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
67000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37300000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3800000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17900000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3100000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14400000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products.</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and six-month periods ended June 30, 2021 and 2020, respectively, the Company did not enter into any</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
CY2021Q2 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.88
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.88
CY2020Q2 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.66
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.71
CY2021Q2 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.12
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.12
CY2020Q2 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.34
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.29
CY2021Q2 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
800000
CY2020Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
700000
CY2021Q2 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
813000
CY2020Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
670000
CY2021Q2 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1576000
CY2020Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1609000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2389000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2279000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
333000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
374000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2056000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1905000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
100000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
400000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
900000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
2000000.0
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9134000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2938000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7721000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9134000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2938000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7721000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9134000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2938000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7721000
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14000000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.03
CY2021Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
14400000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q2 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
400000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1300000
CY2020Q2 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
800000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1500000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
biol Share Based Compensation Arrangement By Share Based Payment Award Recognized Weighted Average Expected Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardRecognizedWeightedAverageExpectedDate
2022-06
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
366000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
801000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1297000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1519000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.03
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0069
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0037
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2398000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53000
biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
20000
biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
1.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.87
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2318000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
405000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2222000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
396000
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
91000
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.48
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
95000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.83
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
365000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
58000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
387000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
134000
CY2021Q1 biol Proceeds From Warrant Exercise
ProceedsFromWarrantExercise
15000000.0
CY2020Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18500000
CY2021Q2 biol Temporary Equity Conversion Of Preferred Stock Into Common Stock
TemporaryEquityConversionOfPreferredStockIntoCommonStock
261
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
4346000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3721000
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1601000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6768000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1158000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6278000
CY2021Q2 us-gaap Inventory Net
InventoryNet
12715000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11157000
CY2021Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
700000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
700000
CY2021Q2 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8573000
CY2020Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8269000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7829000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7664000
CY2021Q2 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
744000
CY2020Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
605000
CY2021Q2 us-gaap Land
Land
172000
CY2020Q4 us-gaap Land
Land
177000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
916000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2021Q2 us-gaap Goodwill
Goodwill
2900000
CY2020Q4 us-gaap Goodwill
Goodwill
2900000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2982000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3552000
CY2021Q2 biol Settlement Liability Accrual Classified Current
SettlementLiabilityAccrualClassifiedCurrent
651000
CY2020Q4 biol Settlement Liability Accrual Classified Current
SettlementLiabilityAccrualClassifiedCurrent
0
CY2021Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
551000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
748000
CY2021Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
328000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
165000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
259000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
281000
CY2021Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
353000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
885000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
378000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
305000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
959000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
731000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6461000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6667000
CY2021Q2 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
400000
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1396000
CY2020Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1158000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1132000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1110000
CY2021Q2 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
140000
CY2020Q2 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-261000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
804000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-18000
CY2021Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
478000
CY2020Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
43000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
878000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
238000
CY2021Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1058000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
854000
CY2021Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1058000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
854000
CY2021Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
507000
CY2020Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
194000
CY2021Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
507000
CY2020Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
194000
CY2021Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
551000
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
660000
CY2021Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
551000
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
660000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
13403000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16186000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
700000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12703000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16186000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2021Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1225
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
886000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2100000
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1716000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2800000
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
1393000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9400000
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
1899000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1000
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
8000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
149000
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest In Year After Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive
88000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14450000
CY2021Q2 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
5990000
biol Warrants Adjusted Exercise Price
WarrantsAdjustedExercisePrice
0.60
CY2021Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
197000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
188000
us-gaap Operating Lease Payments
OperatingLeasePayments
263000
us-gaap Operating Lease Payments
OperatingLeasePayments
330000
CY2021Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48000
CY2020Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
570000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
570000
CY2021Q2 biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P4Y2M12D
CY2020Q2 biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P4Y6M
biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P4Y2M12D
biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P4Y6M
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
608000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
585000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
590000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
539000
CY2021Q2 biol Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
243000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2565000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
585000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1980000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
378000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1602000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1980000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1800000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2021Q2 us-gaap Payments For Rent
PaymentsForRent
200000
us-gaap Payments For Rent
PaymentsForRent
400000
CY2020Q2 us-gaap Payments For Rent
PaymentsForRent
200000
us-gaap Payments For Rent
PaymentsForRent
400000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
319000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
577000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
591000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
589000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
489000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2565000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
585000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1980000
CY2021Q1 biol Litigation Settlement Shares Issued
LitigationSettlementSharesIssued
500000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
600000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9134000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2938000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7721000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
916000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9134000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2938000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7721000
CY2021Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-80000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20000
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.102
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.011
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0000950170-21-001452-index-headers.html Edgar Link pending
0000950170-21-001452-index.html Edgar Link pending
0000950170-21-001452.txt Edgar Link pending
0000950170-21-001452-xbrl.zip Edgar Link pending
biol-20210630.htm Edgar Link pending
biol-20210630.xsd Edgar Link pending
biol-20210630ex31_1.htm Edgar Link pending
biol-20210630ex32_1.htm Edgar Link pending
biol-20210630_cal.xml Edgar Link unprocessable
biol-20210630_def.xml Edgar Link unprocessable
biol-20210630_htm.xml Edgar Link completed
biol-20210630_lab.xml Edgar Link unprocessable
biol-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending